WS3.1 Changing incidence of CF in Ireland?

P. Mavroe1, G. Roche1,2, C. Greenwood1, D. Cooney1, M. Rogers2, S. Roring2, T. McDowell2, D.E. Barton2, 1Children’s University Hospital, National Newborn Bloodspot Screening Laboratory, Dublin 1, Ireland; 2Our Lady's Children's Hospital Crumlin, National Centre for Medical Genetics, Dublin, Ireland

Ireland has the world’s highest incidence of Cystic Fibrosis at approximately 1 in 1400 [1,2]. CF was integrated into the newborn bloodspot screening programme in July 2011 using an IRT/DNA analysis strategy. Babies with a blood IRT above the 99th percentile and with one or two CFTR mutations detected are referred for sweat testing.

The anticipated number of CF cases (54) and carriers (94), were calculated based on the birth rates from the 2008 census and assuming a 2.5-fold enrichment of carriers within the top IRT percentile.

During the first 6 months of the programme, 37,435 babies were screened and 391 (1.0%) were referred for DNA testing. 16 CF cases (all with 2 mutations and confirmed by sweat testing) and 35 unaffected carriers were detected, giving an annualised CF incidence of 1 in 2340.

Just 59% of the predicted number of CF cases (p = 0.038) and 74% of the predicted number of unaffected carriers (p = 0.014) were detected. Data from 2010 indicates a reduced annualised CF incidence of 1 in 2340.

Reference(s)

WS3.2 Who is reported in the Belgian, Dutch and French CF registries?

M. Thomas1, C. Castellani2, H. Cuppens3, V. Gulman4, L. Lemonnier5, A. Norek6, F. Vermeulen7, K. De Boeck8, 1Scientific Institute of Public Health, Public Health and Surveillance on behalf of the Members of the Belgian Cystic Fibrosis (BMR-BFM), Brussels, Belgium; 2Azienda Ospedaliera Universitaria Integrata, Cystic Fibrosis Centre, Verona, Italy; 3EKLLeuven, Center for Human Genetics, Leuven, Belgium; 4Dutch CF Foundation (NCFS), Baarn, Netherlands; 5Inserm la Mucocecidose, Paris, France; 6Institute of Mother and Child, Warsaw, Poland; 7UZ Leuven, Department of Pediatrics, Leuven, Belgium

Inclusion criteria of subjects in CF registries can vary over time and between countries which may introduce bias when data are used for benchmarking. We explored whether the subjects included in 2009 in 3 national CF registries [Belgium (BE), The Netherlands (NL), France (FR)] fulfilled strict diagnostic criteria: sweat test (ST) chloride >60 mEq/L and/or 2 disease causing CFTR mutations identified as specified in the CFTR2 project (access via courtesy of P Nosnay and G Cutting).

Country | BE | NL | F
--- | --- | --- | ---
Total n | 1129 | 1299 | 5640
n (%) diagnostic not documented | 117 (10.3%) | 188 (14.5%) | 593 (10.5%)
\( . \text{n} \) (%) <2 CF dcm & no ST | 33 (2.9%) | 178 (13.7%) | 339 (6.0%)
\( . \text{n} \) (%) <2 CF dcm & ST CI <60 | 84 (7.4%) | 10 (0.8%) | 254 (4.5%)
\( . \text{n} \) (%) no CF dcm & ST CI >30 | 4 (0.3%) | 1 (0.1%) | 10 (0.2%)
FS08del homozygotes (%) | 45.9% | 55.3% | 43.6%
PS (%) | 13.2% | 55.4% | 17.0%
median (IQ) age (yr) | 18.8 (10.2–28.9) | 18.0 (9.8–29.6) | 16.0 (8–25)
dcm: disease causing mutations.

Diagnostic is not documented in at least 10% of subjects reported in these 3 CF registries; not reported ST data accounts for 28 to 95% of these cases. No CFTR mutations reported plus ST chloride below 30 mmol/L occurs, but rarely (0.1–0.3%). A common and strict case definition of who should be reported and/or analyzed in CF registries is needed. Efforts should be done to increase accuracy in CF registries e.g. specifically documenting all tests confirming the CF diagnosis.

WS3.3 Longitudinal changes in lung function and risk of death in cystic fibrosis: developing a joint model for the UK population

D. Taylor-Robinson1, M. Whitehead1, R. Smyth2, P. Diggle2,3,4, R. Henderson2, J. Barrett2, 1University of Liverpool, Department of Public Health and Policy, Liverpool, United Kingdom; 2University of Liverpool, Institute of Child Health, Liverpool, United Kingdom; 3Lancaster University, CHICAS, Lancaster, United Kingdom; 4University of Liverpool, Institute of Global Health, Liverpool, United Kingdom; 5Newcastle University, Newcastle, United Kingdom; 6MRC Biostatistics Unit, Cambridge, United Kingdom

Introduction: We outline a novel approach for the joint modelling of lung function and survival in the UK Cystic Fibrosis Population. The aim is to quantify how aspects of an individual cystic fibrosis patient’s longitudinal profile of %FEV1 are related to their survival prognosis.

Methods: We use the UK CF registry and apply recently developed methodology using open-source software (R) for the joint analysis of repeated measurements and time-to-event outcomes. These methods allow examination of association between %FEV1 and covariates such as sex, genotype and screening status, whilst allowing for correlation within patients, trends over time and potentially informative missing values. Key methodological challenges relate to accommodating cohort effects, and biased entry to registry cohorts.

Results: The dataset includes around 46,000 measures of %FEV1 on 8,000 patients seen between 1999 and 2010, and captures 1000 deaths. In our preliminary analysis stratified by birth cohort: For people born in 1975 to 1979, all other things being equal, a 10% higher level of %FEV1 is associated with a halving of the concurrent hazard for death (HR 0.44 CI 0.38 to 0.50). People with a stable %FEV1, compared to a 1% per year decline, have a 10% lower hazard of death for every year that passes (HR 0.9 CI 0.89 to 0.92).

Conclusions: We apply a novel modelling approach to quantify how longitudinal changes in lung function are related to survival. Both an increased rate of decline in lung function, and a decreased absolute level of lung function are associated with an increased risk of death.

WS3.4 Determinants of lung disease progression in children with CF

P. Farrell1, Z. Li1, D. Sanders1, H. Lai2, A. Laxova1, M. Rock1, H. Levy3, J. Collins3, C. Fierec3, 1University of Wisconsin School of Medicine and Public Health, Madison, United States; 2University of Wisconsin, Madison, United States; 3Medical College of Wisconsin, Milwaukee, United States; 4University of Cincinnati, Cincinnati, United States; 5Université de Bretagne Occidentale, Brest, France

Although many risk factors are postulated as important in the progression of CF lung disease, their relative impact over time has been uncertain. The epidemiologic component of the 27 year old Wisconsin Newborn Screening Project afforded us the opportunity to evaluate the significance of 18 potential determinants. For this study, we combined the 132 enrolled subjects of the Screened and Control cohorts to increase power since group comparisons revealed no differences in pulmonary outcomes after adjustment for confounders. Prospective, systematic assessments were performed longitudinally beginning at diagnosis and continuing throughout childhood, including 1579 chest radiographs, scored by the Wisconsin chest xray (WCXR) method, and 1792 pulmonary function tests. Examining 6 intrinsic and 12 extrinsic risk factors and using mainly GEE analysis with adjustments for age, we found that the strongest associations with worsening WCXR scores were genotype, mucoid *Pseudomonas aeruginosa* (MPa) (both its presence and duration), malnutrition (using height percentile <10th), and hospitalizations (reflecting exacerbations). The longitudinal comparisons with FEV1 values generally confirmed the significance of these four factors but the decreases over time were relatively modest compared to the lung disease progression evident in the chest radiographs. In contrast to MPa, neither *Staphylococcus aureus* nor non-mucoid Pa showed a significant association. In addition, meconium ileus and gender were not significant. Our observations support the view that aside from genotype extrinsic factors that can be modified are the major determinants of lung disease progression in children with CF.